Apel­lis nabs pri­or­i­ty re­view for ge­o­graph­ic at­ro­phy pitch; Bris­tol My­ers ex­tends of­fer time­line on Turn­ing Point buy­out

The FDA will de­cide by Nov. 26 whether to ap­prove the first treat­ment for ge­o­graph­ic at­ro­phy sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion, an ir­re­versible dis­ease that leads to vi­sion loss. And the agency won’t hold an ad­comm for it.

The mak­er of the po­ten­tial treat­ment is Apel­lis, which put out long-term da­ta on the drug in March and quashed some mar­ket con­cerns af­ter mixed da­ta last year, with one an­a­lyst peg­ging the chance for ap­proval at 80%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER